The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | The impact of ruxolitinib on the long-term survival of patients with MF
Tiziano Barbui, MD, Bergamo Hospital Research Foundation, Bergamo, Italy, shares some insights into the impact of ruxolitinib on the long-term survival of patients with myelofibrosis (MF). Prof. Barbui first highlights the important role of transplantation in MF, and then goes on to share some real-world data on the use of this agent. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
